*** CHEMICAL IDENTIFICATION ***
RTECS NUMBER : BF3400050
CHEMICAL NAME : Amino acid solution, ED-AC
LAST UPDATED : 199703
DATA ITEMS CITED : 4
SYNONYMS/TRADE NAMES :
* ED-AC
*** HEALTH HAZARD DATA ***
** ACUTE TOXICITY DATA **
TYPE OF TEST : LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE : Oral
SPECIES OBSERVED : Rodent - rat
DOSE/DURATION : 50 gm/kg
TOXIC EFFECTS :
Behavioral - somnolence (general depressed activity)
REFERENCE :
YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu
Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972-
Volume(issue)/page/year: 7,3001,1979
TYPE OF TEST : LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE : Intravenous
SPECIES OBSERVED : Rodent - rat
DOSE/DURATION : 15 gm/kg
TOXIC EFFECTS :
Behavioral - altered sleep time (including change in righting reflex)
Behavioral - convulsions or effect on seizure threshold
Behavioral - ataxia
REFERENCE :
YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu
Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972-
Volume(issue)/page/year: 7,3001,1979
TYPE OF TEST : LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE : Oral
SPECIES OBSERVED : Rodent - mouse
DOSE/DURATION : 50 gm/kg
TOXIC EFFECTS :
Lungs, Thorax, or Respiration - respiratory stimulation
Gastrointestinal - hypermotility, diarrhea
Skin and Appendages - hair
REFERENCE :
YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu
Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972-
Volume(issue)/page/year: 7,3001,1979
TYPE OF TEST : LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE : Intravenous
SPECIES OBSERVED : Rodent - mouse
DOSE/DURATION : 7500 mg/kg
TOXIC EFFECTS :
Behavioral - altered sleep time (including change in righting reflex)
Behavioral - convulsions or effect on seizure threshold
Behavioral - ataxia
REFERENCE :
YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu
Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972-
Volume(issue)/page/year: 7,3001,1979
*** END OF RECORD ***
|
|
|
ALL Chemical Property And Toxicity Analysis PAGES IN THIS GROUP
| NAME | CAS |
Amine curing agent, CD 16005
| 597-40-0 |
Amine curing agent, CD 16009
| 597-40-0 |
Amine curing agent, CD 16018 A
| 597-40-0 |
Amine curing agent, CD 16019 A
| 597-40-0 |
Amine curing agent, XH 713-50
| 597-40-0 |
Amines, C(sub 18-20)-tert-alkyl
| 69225-84-9 |
Amines, C10-18-alkyl, hydrochlorides
| 80448-80-2 |
Albumin, egg
| 9006-59-1 |
Amines, N-C12-18-alkyltrimethylenedi-
| 68155-37-3 |
Amines, coco alkyl, benzoates
| 68526-65-8 |
Amines, N-coco alkyltrimethylenedi-
| 61791-63-7 |
Amines, N-coco alkyltrimethylenedi-, acetates
| 61791-64-8 |
Amines, N-coco alkyltrimethylenedi-, adipates
| 68155-42-0 |
Amines, N-coco alkyltrimethylenedi-, benzoates
| 68188-29-4 |
Amines, N-coco alkyltrimethylenedi-, glycolates
| 68155-43-1 |
Amines, hydrogenated tallow alkyl, acetates
| 61790-59-8 |
Amines, N-soya alkyltrimethylenedi-
| 61791-67-1 |
Amines, tallow alkyl, acetates
| 61790-60-1 |
Albumin, from grape seed
| 61790-60-1 |
Amines, N-tallow alkyltrimethylenedi-, diacetates
| 68911-78-4 |
Amines, tri-C(sub 8-10)-alkyl-
| 68814-95-9 |
Amino acid granule for heptic encephalopathy, MHS-G
| 68814-95-9 |
Amino acids, BCAA-GSUBSTANCE DEFINITION :Consists of 3 branched amino acids, L-isoleucine, L-leucine and L-valineREFERENCE :KSRNAM Kiso to Rinsho. Clinical Report. (Yubunsha Co., Ltd., 1-5, KandaSuda-Cho, Chiyoda-ku, KS Bldg., Tokyo 101, Japan) V.1- 1960-Volume(issue)/page/year: 23,1843,1989
| 68814-95-9 |
Amino acid solution, ED-AC
| 68814-95-9 |
Amino acid solution for patients with hepaticencephalopathy, MHS-2
| 68814-95-9 |
Amino acid solution for renal failure, MRX-III
| 68814-95-9 |
Amino acid for renal insufficinecy, AMI-U-II
| 68814-95-9 |
Amino acid solution for renal insufficiency, TO-70
| 68814-95-9 |
Amino acid solution, Ispol
| 68814-95-9 |
Albumin, human serum sonicated
| 68814-95-9 |
Amino acid solution, Moriamin
| 68814-95-9 |
Amino acid solution, Moriamin-S
| 68814-95-9 |
Amino acids solution, MPR-F
| 65072-01-7 |
Amino acids solution, P-1
| 65072-01-7 |
Amino acid solution, TA 7.2
| 65072-01-7 |
Amino acid solution, TAT-7180H
| 65072-01-7 |
Amino acid solution, TAT-7180L
| 65072-01-7 |
Amino acids solution, CNT(H)
| 65072-01-7 |
Amino acids solution, CNT(L)
| 65072-01-7 |
Amino acids solution, CSH
| 65072-01-7 |
Albumin, pyrolyzate
| 65072-01-7 |
Amino acids solution, GA-1080(H)
| 65072-01-7 |
Amino acids solution, GM-1
| 65072-01-7 |
Amino acids solution, GM-2
| 65072-01-7 |
Amino acids solution, TAB-1
| 65072-01-7 |
Amino acids solution, TAB-2
| 65072-01-7 |
Aminoacylase
| 9012-37-7 |
alpha-Aminoimidazole-4-propionic acid, cobalt(2+)salt
| 14873-10-0 |
Amipramine, hydrochloride
| 14873-10-0 |
Amipurimycin, hydrateSUBSTANCE DEFINITION :Isolated from culture filtrate of Streptomyces novoguineesis T-36496REFERENCE :JANTAJ Journal of Antibiotics. (Japan Antibiotics Research Assoc., 2-20-8Kamiosaki, Shinagawa-ku, Tokyo, 141, Japan) V.2-5, 1948-52; V.21- 1968-
| 14873-10-0 |
|
|